Actuate Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Actuate Therapeutics, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of 1.33 million common shares by existing stockholders, highlighting significant financial challenges including a going concern warning.
NASDAQ
S-1: Actuate Therapeutics Files for $50 Million Common Stock Offering via B. Riley Purchase Agreement
Actuate Therapeutics intends to offer up to 3,904,374 shares of common stock through a committed equity facility with B. Riley Principal Capital II, potentially raising up to $50 million for working capital and general corporate purposes.
NASDAQ
Actuate Therapeutics files for an IPO to raise $29.5 million, aiming to advance its cancer therapies and list on the Nasdaq Capital Market.
NASDAQ
Actuate Therapeutics updates its S-1 filing, detailing the initial public offering of 2,777,778 shares of common stock with an estimated price range of $8.00 to $10.00 per share.
NASDAQ
Actuate Therapeutics updates its S-1 filing, highlighting clinical trial advancements and plans for its lead drug, elraglusib, in treating metastatic pancreatic cancer and other malignancies.
NASDAQ
S-1/A: Actuate Therapeutics Files Amendment No. 2 for Initial Public Offering, Targeting Cancer Therapies
Actuate Therapeutics advances its IPO plans with an updated filing, focusing on developing cancer therapies through GSK-3 inhibition.
NASDAQ
Actuate Therapeutics amends its S-1 filing, highlighting promising interim results from its Phase 2 trial of elraglusib in metastatic pancreatic cancer and plans for upcoming clinical trials.
NASDAQ
Actuate Therapeutics, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an initial public offering, planning to list its common stock on the Nasdaq Capital Market under the ticker symbol 'ACTU'.